<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452334</url>
  </required_header>
  <id_info>
    <org_study_id>CA210-003</org_study_id>
    <nct_id>NCT01452334</nct_id>
  </id_info>
  <brief_title>Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy</brief_title>
  <official_title>A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death-Ligand 1 (PD-L1) Antibody (BMS-936559) in Subjects With Relapsed or Refractory Hematologic Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the side effects of treatment with the monoclonal
      antibody anti-PD-L1 (BMS-936559) in subjects with compromised bone marrow function and the
      dose that should be recommended for use in future studies.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Weeks 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of BMS-936559 as measured by the incidence of adverse events (AEs), serious AEs, dose-limiting toxicities, laboratory test abnormalities, and changes in vital signs</measure>
    <time_frame>Every 2 weeks until 70 days after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by maximum observed serum concentration (Cmax)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by time of maximum observed serum concentration (Tmax)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by area under the serum concentration time curve in the dosing interval [AUC(TAU)]</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by accumulation index (AI) calculated ar ratio of the AUC(TAU) at steady state and first dose</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by serum concentration achieved at the end of dosing interval (trough concentration) (Cmin)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BMS-936559 as measured by serum concentration achieved at the end of the infusion (Ceoinf)</measure>
    <time_frame>Within the first 22 weeks, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity of BMS-936559 as measured by the objective response rate, duration of response, and progression free survival</measure>
    <time_frame>Week 4, week 12, week 20, and every 16 weeks until confirmed disease progression assessed up to Week 214</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of BMS-936559 as measured by the frequency of subjects with an increase in anti-drug antibody levels from baseline</measure>
    <time_frame>Baseline, weeks 3, weeks 12, weeks 20, weeks 34, weeks 46, and at follow-up (35 ± 7 days after last treatment and 70-90 days since last treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Programmed death ligand 1 (PD-L1) receptor occupancy levels as measured by changes from baseline</measure>
    <time_frame>Baseline and within the first 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm 1: BMS-936559</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-936559 (Anti PD-L1)</intervention_name>
    <description>Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response</description>
    <arm_group_label>Arm 1: BMS-936559</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance of 0 or 1

          -  Subjects must have histological confirmation of relapsed or refractory hematologic
             malignancy

          -  Subjects with non-Hodgkin's lymphoma or Hodgkin lymphoma must have at least one
             measureable lesion as defined by lymphoma response criteria. Tumor sites that are
             considered measureable must not have received prior radiation therapy

          -  Subjects with multiple myeloma (MM) must have detectable disease as measured by
             presence of monoclonal immunoglobulin protein in a serum electrophoresis: IgG, IgA,
             IgM, (M-protein ≥ 0.5 g/dl or serum IgD M-protein ≥ 0.05 g/dl) or serum free-light
             chain or 24 hour urine with free light chain. Excluded are subjects with only
             plasmacytomas, plasma cell leukemia, or non-secretory myeloma

          -  Subjects with chronic myelogenous leukemia (CML) must have evidence of the
             Philadelphia chromosome by polymerase chain reaction (PCR) or chromosome analysis

          -  Life expectancy of at least 3 months

          -  For subjects with lymphoma, either a formalin fixed tissue block or 7 to 15 slides of
             tumor sample (archival or fresh) must be available for performance of correlative
             studies

          -  Subjects must have received at least one prior chemotherapy regimen. Subjects must be
             off therapy for at least 4 weeks ( 2 weeks for oral agents) prior to Day 1

          -  Prior palliative radiation must have been completed at least 2 weeks prior to study
             Day 1

          -  Toxicities related to prior therapy must have returned to Grade 1 or less, except for
             alopecia. Peripheral neuropathy must be Grade 2 or less

          -  Adequate bone marrow function defined as:

               1. Absolute neutrophil count ≥ 1000/μl (stable off any growth factor within 1 week
                  of study drug administration)

               2. Hemoglobin ≥ 9 g/dL (transfusion to achieve this level is permitted)

               3. Platelet count ≥ 50 X 103/ μl (transfusion to achieve this level is not
                  permitted)

          -  Adequate renal parameters defined as Creatinine clearance (CrCl) &gt; 40 ml/min
             (Cockcroft-Gault formula)

          -  Adequate hepatic parameters defined as:

               1. Aspartate aminotransferase (AST) ≤ 3 x ULN

               2. Alanine aminotransferase (ALT) ≤ 3 x ULN

               3. Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert's Syndrome, who must have
                  total bilirubin &lt; 3.0 mg/dL and direct bilirubin &lt; 0.5 mg/dL)

          -  Women of child bearing potential (WOCBP) and for at least 70 days after the last dose
             of investigational product

          -  Men and women ≥ 18 years of age

        Exclusion Criteria:

          -  Subjects with acute leukemias, blast phase CML, T cell lymphoblastic or Burkitt
             lymphoma

          -  Subjects with a history of central nervous system involvement by hematologic
             malignancy or symptoms suggestive of central nervous system involvement

          -  Subjects with concomitant second malignancies (except adequately treated
             nonmelanomatous skin cancers, ductal carcinoma in situ, treated superficial bladder
             cancer or prostate cancer or in situ cervical cancers) are excluded unless a complete
             remission was achieved at least 3 years prior to study entry and no additional therapy
             is required or anticipated to be required during the study period

          -  Subjects with any active autoimmune disease or a history of known or suspected
             autoimmune disease, or history of syndrome that requires systemic corticosteroids or
             immunosuppressive medications, except for subjects with vitiligo or resolved childhood
             asthma/atopy

          -  A serious uncontrolled medical disorder or active infection which would impair the
             ability of the subject to receive protocol therapy or whose control may be jeopardized
             by the complications of this therapy

          -  Prior therapy with an anti programmed death-1 (anti-PD-1), anti Programmed death
             ligand 1 (anti-PD-L1), anti Programmed death ligand 2 (anti-PD-L2), anti-CD137 or anti
             Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (or any other
             antibody or drug specifically targeting T-cell costimulation or checkpoint pathways)

          -  Non-oncology vaccine therapies for prevention of infectious diseases (eg seasonal flu
             vaccine, Human Papilloma Virus (HPV) vaccine) within 4 weeks of study drug
             administration Vaccination while on study is also prohibited except for administration
             of the inactivated influenza vaccine

          -  Prior organ allograft or allogeneic bone marrow transplantation

          -  Positive for human immunodeficiency virus (HIV 1/2) or known acquired immunodeficiency
             syndrome (AIDS)

          -  Positive tests for hepatitis B virus surface antigen (HBsAg), or antibody to hepatitis
             B core Ag or hepatitis C virus antibody (confirmed by Western Blot) or hepatitis C
             ribonucleic acid (RNA) in serum

          -  Ejection fraction less than 45% in subjects with prior anthracycline exposure

          -  History of Grade 4 anaphylactic reaction to monoclonal antibody therapy

          -  Women who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>February 22, 2012</last_update_submitted>
  <last_update_submitted_qc>February 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

